BIRMINGHAM, Ala., May 2, 2025 /PRNewswire/ -- Encompass Health is pleased to announce the opening of its request for 2025 research grant applications due Sept. 30, 2025, at 5 p.m. EST. The grants, totaling up to $60,000, will be awarded for the investigation of the impact or effectiveness of therapies in the inpatient rehabilitation facility post-acute care setting, knowledge translation or implementation science. Grant recipients do not have to be affiliated with Encompass Health and research does not have to be conducted in an Encompass Health inpatient rehabilitation hospital.
High-priority topics include:
Applications will be evaluated based on scientific merit, experience of principal investigator(s), relevance to the grant program objectives, expected outcomes and study feasibility. The research should be completed no more than 12 months after receiving the grant and must be conducted in the United States or Puerto Rico. Final selection of recipients and programs will be made by Oct. 30, 2025.
A copy of the application and the full details may be found at encompasshealth.com/therapy-grants.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 167 hospitals in 38 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies™, Becker's Hospital Review's 150 Top Places to Work in Healthcare and Forbes' Most Trusted Companies in America. For more information, visit encompasshealth.com, or follow us on our newsroom, X, Instagram and Facebook.
From Fortune. © 2025 Fortune Media IP Limited. All rights reserved. Fortune® is a registered trademark and Fortune World's Most Admired Companies™ is trademark of Fortune Media IP Limited and are used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of, Encompass Health. From Forbes © 2024 Forbes Media LLC. All rights reserved. Used under license.
Media contact:
Polly Manuel | 205-970-5912
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$126.05 |
Daily Change: | -0.75 -0.59 |
Daily Volume: | 448,002 |
Market Cap: | US$12.700B |
August 07, 2025 August 04, 2025 June 18, 2025 April 24, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load